- June 6, 2020
- Posted by: admin
- Category: DPN Topics
Subject: Science and tech
The World Health Organization said that clinical trials of the repurposed anti-malaria drug hydroxychloroquine for treatment of covid-19 will resume, after a committee reviewed the available data for the drug.
- Solidarity” is an international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.
- The Solidarity trial will compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19.
- By enrolling patients in multiple countries, the Solidarity trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival.
- Over 90 countries including India are working together to find effective therapeutics as soon as possible, via the trial.
- Four treatment options:
- The chloroquine-hydroxychloroquine combination to prevent entry of virus using ACE 2 receptor
- Lopinavir-ritonavir to prevent replication of virus by inhibiting enzymes used for replication
- By understanding structure
- By understanding virus behavior
- WHO says that while randomized clinical trials normally take years to design and conduct, the Solidarity Trial will reduce the time by 80%.
- The Union health ministry has permitted the trial for four drugs: Remdesivir, Lopinavir, Interferon (beta-1a) and hydroxychloroquine or chloroquine.